Managing Partner, Gurnet Point Capital
Chris Viehbacher is the Managing Partner of Gurnet Point Capital. Gurnet Point is a Boston based investment fund associated with the Bertarelli family and has a $2 billion capital allocation. Viehbacher is a Board member of Axcella Health, BEFORE Brands, Crossover Health and PureTech Health plc. He is also Chairman of Boston Pharmaceuticals, a Gurnet Point portfolio company and Vedanta, a PureTech portfolio company as well as Vice Chairman for Nuvelution Pharmaceuticals. He is also a member of The Board of Trustees of Northeastern University. Viehbacher is the former CEO and Member of the Board of Directors of Sanofi, a Fortune 50 Biopharmaceutical company based in Paris. He was also the Chairman of the Board of Genzyme in Boston. Prior to joining Sanofi, Viehbacher spent 20 years with GlaxoSmithKline in Germany, Canada, France and, latterly, the U.S. as President of GSK North America. He was a Member of the Board of Directors of GSK plc in London and Co-President of GSK's Portfolio Management Board. Viehbacher began his career with Price Waterhouse after graduating with a degree in Commerce at Queen's University in Canada.